Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years

NCT02669121 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02669121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02669121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
June 14, 2016
Completion date
June 16, 2018
Enrollment
4,748 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers